Federated Hermes
LBRX

Federated Hermes’s LB Pharmaceuticals LBRX Stock Holding History

Federated Hermes’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123K Hold
5,000
– – ﹤0.01% 1560
2025
Q4 		$111K Sell
5,000
-4,000
-44% -$69.9K ﹤0.01% 1568
2025
Q3 		$142K Buy
+9,000
New +$143K ﹤0.01% 1541

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Federated Hermes's LBRX Position: Q1 2026 in Review

Federated Hermes held its LB Pharmaceuticals (LBRX) position steady in Q1 2026 at 5,000 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #1560.

Federated Hermes first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $142K in Q3 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Federated Hermes held 5,000 shares of LB Pharmaceuticals worth $123K as of Q1 2026.
  • Federated Hermes left its LB Pharmaceuticals share count unchanged in Q1 2026.
  • LB Pharmaceuticals made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1560 holding.
  • Federated Hermes first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Federated Hermes's LB Pharmaceuticals position peaked at $142K in Q3 2025.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.